The €173 million (US$187 million) in capital that Earlybird Health recently raked in from investors will go towards bolstering investment in European health care startups, many of which are still recovering from the impact of COVID-19, Thom Rasche, a partner at Earlybird Health, told BioWorld. The fund is looking to invest in the technologies that can improve patient care.